Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (251-260 of 337) with videos related to

Pageof 34
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
NPJ Vaccines|April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humansKelly E Seaton, Aaron Deal, Xue Han, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Viruses|July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy AssessmentRaabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
Pageof 34

Showing results (251-260 of 337) with videos related to

Sort By:
Pageof 34
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
NPJ Vaccines|April 16, 2021
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humansKelly E Seaton, Aaron Deal, Xue Han, et al.
Plos One|January 31, 2020
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South AfricansLue Ping Zhao, Andrew Fiore-Gartland, Lindsay N Carpp, et al.
Vaccines|December 10, 2020
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP<sup>®</sup> DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy AdultsSrilatha Edupuganti, Stephen C De Rosa, Marnie Elizaga, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Viruses|July 7, 2019
Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-infection Estimation towards Enhanced Vaccine Efficacy AssessmentRaabya Rossenkhan, Morgane Rolland, Jan P L Labuschagne, et al.
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Plos One|February 8, 2014
Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infectionSusan Zolla-Pazner, Allan deCamp, Peter B Gilbert, et al.
Journal of Virology|August 17, 2012
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyMattia Bonsignori, Justin Pollara, M Anthony Moody, et al.
Pageof 34